ट्रायल रडार AI | ||
|---|---|---|
क्लिनिकल ट्रायल NCT06698510 (ADOPTpilot) के लिए शिस्टोसोमियासिस वर्तमान में भर्ती जारी है। सभी विवरणों के लिए क्लिनिकल ट्रायल रडार कार्ड दृश्य और AI खोज उपकरण देखें, या यहाँ कुछ भी पूछें। | ||
एक परीक्षण फ़िल्टर मानदंडों से मेल खाता है
कार्ड दृश्य
Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study (ADOPTpilot) 18,500 बच्चों के अनुकूल रियल-वर्ल्ड एविडेंस निवारक
चिकित्सा परीक्षण का विवरण मुख्य रूप से अंग्रेजी में उपलब्ध है। हालाँकि, ट्रायल रडार AI मदद कर सकता है! बस 'अध्ययन समझाएं' पर क्लिक करें और अपनी चुनी हुई भाषा में परीक्षण की जानकारी देखें और चर्चा करें।
क्लिनिकल ट्रायल NCT06698510 (ADOPTpilot) एक अवलोकनात्मक चिकित्सकीय अध्ययन है जो शिस्टोसोमियासिस से जुड़ा हुआ है। परीक्षण वर्तमान में भर्ती जारी चल रहा है। इसकी शुरुआत 25 नवंबर 2024 को हुई थी, और इसमें कुल 18,500 प्रतिभागियों के नामांकन की योजना है। Peter Steinmann इस परीक्षण का नेतृत्व कर रहे हैं और इसके 1 मार्च 2026 तक पूरा होने की उम्मीद है। ClinicalTrials.gov वेबसाइट पर यह जानकारी 24 सितंबर 2025 को अंतिम बार अपडेट की गई थी।
संक्षिप्त सारांश
The proposed small-scale pilot studies are public health intervention studies implemented through established routine programs and services in the frame of the mass drug administration (MDA) campaigns in Côte d'Ivoire, Kenya and Uganda. In each country two most promising health intervention platforms were selected for pilot distribution of arpraziquantel 150mg (arPZQ).
The aim of the small-scale pilot study is to as...
और दिखाएँआधिकारिक शीर्षक
Arpraziquantel for Schistosomiasis Control in Preschool-aged Children in Endemic Areas in Kenya and Côte d'Ivoire: A Small-scale Public Health Intervention Study Arpraziquantel for Schistosomiasis Control in Preschool-aged Children in Endemic Areas in Uganda, With Special Consideration of Dose Determination Methods: a Small-scale Public Health Intervention Study in Hoima and Bugiri Districts
स्वास्थ्य स्थितियां
शिस्टोसोमियासिसअन्य अध्ययन आईडी
- ADOPTpilot
- 2108p
- RIA2019IR-2895; G2020-102 (अन्य अनुदान/वित्त पोषण संख्या) (European and Developing Countries Clinical Trials Partnership (EDCTP); Global Healh Innovative Technology (GHIT) Fund)
NCT नंबर
अध्ययन प्रारंभ तिथि (वास्तविक)
2024-11-25
अंतिम अद्यतन प्रकाशित
2025-09-24
अध्ययन की समाप्ति तिथि (अनुमानित)
2026-03
नामांकन (अनुमानित)
18,500
अध्ययन प्रकार
अवलोकनात्मक
स्थिति
भर्ती जारी
प्रमुख शब्द
schistosomiasis
preschool-aged children
praziquantel
arpraziquantel
deworming
pediatric treatment
child health
preschool-aged children
praziquantel
arpraziquantel
deworming
pediatric treatment
child health
समूह/हस्तक्षेप
| प्रतिभागी समूह/शाखा | हस्तक्षेप/उपचार |
|---|---|
arPZQ distributed through Platform 1 (NTD programmes) Preschool-aged children (24 to 59 months of age) of villages preselected to receive a single oral dose of 50mg/kg or 60mg/kg (depending on country) arpraziquantel as part of the routine schistosomiasis mass drug administration campaigns led by the national NTD programmes. | Arpraziquantel 150mg dispersible tablet Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg/kg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg/kg (in Côte d'Ivoire; for mixed infections with S. mansoni / S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics. |
arPZQ distributed through Platform 2 (child health days/nutrition programmes) Preschool-aged children (24 to 59 months of age) of villages preselected to receive a single oral dose of 50mg/kg or 60mg/kg (depending on country) arpraziquantel as part of the routine vitamin A distribution/child health days campaigns led by the national nutrition programmes. | Arpraziquantel 150mg dispersible tablet Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg/kg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg/kg (in Côte d'Ivoire; for mixed infections with S. mansoni / S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics. |
प्राथमिक परिणाम माप
द्वितीयक परिणाम माप
| परिणाम माप | माप विवरण | समय सीमा |
|---|---|---|
Platform performance for arPZQ distribution | Platform performance will be combined measure based on the coverage and feasibility measured by the following parameters and implementation outcome indicators:
* Platform reach: Program reach and therapeutic coverage
* Platform feasibility: Extent of changes to established procedures and requirements in terms of resources for social mobilization, training, drug logistics and drug delivery Feasibility will be assessed through quantitative and qualitative data on operational aspects
* Platform acceptability/suitability: quantitative and qualitative feedback by stakeholders (health system \& population perspective) assessed through Questionnaires \& FGDs with parents and community stakeholders, KIIs and transect walks with health workers and programmatic supervision/monitoring tools and review meetings of implementers
For the analysis and selection of a platform, a prioritization matrix will be developed which enables a triangulation and weighing of the above mentioned indicators. | Documentation from 3 months before up to 12 weeks after the drug distribution |
| परिणाम माप | माप विवरण | समय सीमा |
|---|---|---|
Effectiveness of social mobilization, communication and training | The effectiveness of the advocacy, social mobilization and communication campaign will be measured as a combined measure by the following indicators:
* Appropriateness of the tools (content, distribution channel, locations, timetable)
* Acceptability of messages and motivation to access treatment
* Coverage and scope of social mobilization
* Feasibility in terms of equipment, personnel and timetable using questionnaires, FGDs, KIIs, non-participative observations through social scientists and routine monitoring and supervision tools as well as training knowledge assessment forms applied by the platforms and monitoring and evaluation teams.
For the analysis and selection of a platform with regard to its social mobilization and communication effectiveness, a prioritization matrix will be developed which enables a triangulation and weighing of the above mentioned indicators. | Documentation from 3 months before up to 12 weeks after the drug distribution |
भागीदारी सहायक
पात्रता मानदंड
- Living in the designated implementation area since at least 6 months
- Aged between 24 - 59 months
- Informed consent available
- No acute or chronic illness and/or inability to take oral medication
- No reported history of seizures
- No known allergic response to praziquantel
Peter Steinmannअध्ययन उत्तरदायी पक्ष
Peter Steinmann, प्रायोजक-अन्वेषक, Unit Head, Swiss Tropical & Public Health Institute
अध्ययन केंद्रीय संपर्क
संपर्क: Peter Steinmann, PhD PD, +41 61 284 82 18, [email protected]
संपर्क: Nora Monnier, Dr. med., +41 61 284 82 29, [email protected]
7 3 देशों में अध्ययन स्थान
Programme National de Lutte Contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CP), Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (MSHPCMU), Abidjan, Côte d’Ivoire
Alain-Claver Kouamin, Dr. med., संपर्क, +225 07 07 40 32 34, [email protected]
भर्ती जारी
Université Félix Hophouët-Boigny (UFHB), Département de sociologie, Abidjan, Côte d’Ivoire
Alain Toh, Prof., संपर्क, +225 07 07 14 63 46, [email protected]
भर्ती जारी
Université Félix Hophouët-Boigny (UFHB), UFR Biosciences, Abidjan, Côte d’Ivoire
Eliézer K. N'Goran, Prof., संपर्क, +225 01 03 48 88 83, [email protected]
भर्ती जारी
African Institute for Health and Development (AIHD), Nairobi, Kenya
Mary Amuyunzu-Nyamongo, Prof., संपर्क, +254 733-366229, [email protected]
अभी भर्ती शुरू नहीं
Kenya Medical Research Institute (KEMRI), Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Nairobi, Kenya
Sammy M. Njenga, Prof., संपर्क, +254 735-173372, [email protected]
अभी भर्ती शुरू नहीं
Makerere University, Department of Sociology and Anthropology, Kampala, Uganda
Stella Neema, Prof., संपर्क, +256 772457576, [email protected]
अभी भर्ती शुरू नहीं
Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Kampala, Uganda
Prudence Beinamaryo, Dr., संपर्क, +256-789-548-930, [email protected]
अभी भर्ती शुरू नहीं